Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
The DOI matches its Crossref record; 180 of the 180 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, most of the activities of transcription factors are mediated by protein-protein interaction or binding to DNA in a sequence-specific fashion, both of which are conventionally considered challenging targets for development of small-molecule inhibitors (2).”
From Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. (2005) · cites this paper as [2]
In the citing paper
“Undruggable proteins, which possess flat active sites, often act through PPI networks, which are characterized by large, flat, and undefined interfaces between proteins. These networks have been considered undruggable biological processes for decades.309–311”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [310]
Citations
Cites
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Nitric oxide synthases: structure, function and inhibition
ALDERTON, W. K., COOPER, C. E., & KNOWLES, R. G. (2001) · Biochemical Journal · doi:10.1042/bj3570593 · Cited by 4,110
The Bcl2 family: regulators of the cellular life-or-death switch
Cory, S., & Adams, J. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc883 · Cited by 4,032
BCL-2 family members and the mitochondria in apoptosis
Gross, A., McDonnell, J. M., & Korsmeyer, S. J. (1999) · Genes & Development · doi:10.1101/gad.13.15.1899 · Cited by 3,641
Nitric oxide and the immune response
Bogdan, C. (2001) · Nature Immunology · doi:10.1038/ni1001-907 · Cited by 3,447
Ghrelin: Structure and Function
Kojima, M., & Kangawa, K. (2005) · Physiological Reviews · doi:10.1152/physrev.00012.2004 · Cited by 2,810
CTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
The mechanism of action of cyclosporin A and FK506
Schreiber, S. L., & Crabtree, G. R. (1992) · Immunology Today · doi:10.1016/0167-5699(92)90111-j · Cited by 2,127
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,041
Anatomy of hot spots in protein interfaces
Bogan, A. A., & Thorn, K. S. (1998) · Journal of Molecular Biology · doi:10.1006/jmbi.1998.1843 · Cited by 1,988
Research works printed but not linked: 4
- Das, R. C. & Morrow, K. J. J. in Antibody Engineering Report (Drug and Market Development Publications, 2002).
- Gibson, C. et al. Nonpeptidic α(v)β(3) Integrin antagonist libraries: on-bead screening and mass spectrometric identification without tagging. Angew. Chem. Int. Ed. Engl. 40, 165–169 (2001). · doi:10.1002/1521-3773(20010105)40:1<165::aid-anie165>3.0.co;2-8
- Raimundo, B. C. et al. Discovery of small-molecule inhibitors of interleukin-2 using fragment assembly. J. Med. Chem. (in the press). References 56–59 (and 62 below) detail an interdisciplinary approach, integrating fragment-based discovery, medicinal chemistry, and structural biology, to discovering inhibitors of the IL-2/IL-2R interaction.
- Hajduk, P. J. et al. High-throughput nuclear magnetic resonance-based screening. J. Med. Chem. 42, 2315–2317 (1999). · DOI · Paper page
Cited by
Items 401–500 of 1,003
Khanna, M., Wang, F., Jo, I., Knabe, W. E., Wilson, S. M., Li, L., Bum‐Erdene, K., Li, J., Sledge, G. W., Khanna, R., et al. (2011) · ACS Chemical Biology · doi:10.1021/cb200180m · Cited by 59
“1a) poses the same challenges that have plagued prior efforts to inhibit protein-protein interactions with small molecules (17), due to the tightness of the protein-protein interaction (18, 19), the large interaction surface which is estimated at 1,318 Å2 (20), and the inherent flexibility of the target (Fig.”
BackgroundGonzalez, A. Z., Li, Z., Beck, H. P., Canon, J., Chen, A., Chow, D., Duquette, J., Eksterowicz, J., Fox, B. M., Fu, J., et al. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm401911v · Cited by 57
Luchini, A., Espina, V., & Liotta, L. A. (2014) · Nature Communications · doi:10.1038/ncomms5413 · Cited by 62
Multiplex assay for condition-dependent changes in protein–protein interactions
Schlecht, U., Miranda, M., Suresh, S., Davis, R. W., & St.Onge, R. P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204952109 · Cited by 60
Butini, S., Campiani, G., Borriello, M., Gemma, S., Panico, A., Persico, M., Catalanotti, B., Ros, S., Brindisi, M., Agnusdei, M., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701253t · Cited by 64
Wang, H., Chauhan, J., Hu, A., Pendleton, K., Yap, J. L., Sabato, P. E., Jones, J. W., Perri, M., Yu, J., Cione, E., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1108 · Cited by 57
“Another of our originally described Myc inhibitors, 10074-G5 (N-([1,1’-biphenyl]-2-yl)-7-nitrobenzo[c] [1,2,5]oxadiazol-4-amine) [21] binds to a more N-terminal region of Myc’s HLH domain ~35 residues removed from the 10058-F4 binding site [34].”
BackgroundChapter 4 Structure and Function of Regulator of G Protein Signaling Homology Domains
Tesmer, J. J. G. (2009) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(09)86004-3 · Cited by 57
The paramyxovirus polymerase complex as a target for next-generation anti-paramyxovirus therapeutics
Cox, R. M., & Plemper, R. K. (2015) · Frontiers in Microbiology · doi:10.3389/fmicb.2015.00459 · Cited by 57
“…however, natural small molecule products such as rapamycin and cyclosporine spotlighted that only a subset of residues in small hot-spot areas confers most of the binding energy, making PPIs are amenable to small-molecule docking and interference (Arkin and Wells, 2004; Arkin et al., 2014).”
BackgroundSpatial Screening for the Identification of the Bioactive Conformation of Integrin Ligands
Weide, T., Modlinger, A., & Kessler, H. (2006) · Springer eBooks · doi:10.1007/128_052 · Cited by 57
Hu, C.-M., Zhu, J., Guo, X. E., Chen, W., Qiu, X.-L., Ngo, B., Chien, R., Wang, Y., Tsai, C. Y., Wu, G., et al. (2014) · Oncogene · doi:10.1038/onc.2014.67 · Cited by 57
Metz, A., Ciglia, E., & Gohlke, H. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802651553 · Cited by 61
“As it is often not possible to identify well-defined binding pockets at the interface present in the crystal structure of a proteinprotein complex, it is important to go beyond analyzing the static structure of PPIs and take into account protein dynamics [29, 44, 45].”
BackgroundInfluentialNatural Product MDM2 Inhibitors: Anticancer Activity and Mechanisms of Action
Qin, J., Nag, S. A., Voruganti, S., Wang, W., & Zhang, R. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712803988910 · Cited by 58
“Protein–protein interactions usually involve large and flat surfaces that are difficult to interrupt by low molecular weight compounds [145, 146].”
BackgroundKwak, D., Chae, H., Lee, M., Ha, J., Goyal, G., Kim, M. J., Kim, K. B., & Chi, S. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201511601 · Cited by 58
SARS-CoV-2 nucleocapsid and Nsp3 binding: an in silico study
Khan, M. T., Zeb, M. T., Ahsan, H., Ahmed, A., Ali, A., Akhtar, K., Malik, S. I., Cui, Z., Ali, S., Khan, A. S., et al. (2020) · Archives of Microbiology · doi:10.1007/s00203-020-01998-6 · Cited by 69
Molecular machinery of signal transduction and cell cycle regulation in Plasmodium
Koyama, F. C., Chakrabarti, D., & Garcia, C. R. S. (2009) · Molecular and Biochemical Parasitology · doi:10.1016/j.molbiopara.2009.01.003 · Cited by 62
“Although targeting protein–protein interactions can be challenging because of complexity and diversity of binding surfaces, there have been recent progresses towards developing such therapeutic intervention approaches [95].”
BackgroundMoroni, E., Zhao, H., Blagg, B. S. J., & Colombo, G. (2014) · Journal of Chemical Information and Modeling · doi:10.1021/ci4005767 · Cited by 58
Ligand-Independent and Tissue-Selective Androgen Receptor Inhibition by Pyrvinium
Lim, M. A., Otto‐Duessel, M., He, M., Su, L., Nguyen, D., Chin, E., Alliston, T. N., & Jones, J. O. (2013) · ACS Chemical Biology · doi:10.1021/cb400759d · Cited by 58
Mukhopadhyay, A., Maulik, U., & Bandyopadhyay, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032289 · Cited by 58
“Targeting protein-protein interactions has relatively recently been established to be a promising alternative to the conventional approach to drug design [2,3].”
BackgroundSekikaic Acid and Lobaric Acid Target a Dynamic Interface of the Coactivator CBP/p300
Majmudar, C. Y., Højfeldt, J. W., Arevang, C. J., Pomerantz, W. C., Gagnon, J. K., Schultz, P. J., Cesa, L. C., Doss, C. H., Rowe, S. P., Vásquez, V., et al. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201206815 · Cited by 56
Ban, F., Leblanc, E., Li, H., Munuganti, R. S. N., Frewin, K., Rennie, P. S., & Cherkasov, A. R. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500684r · Cited by 56
Buchwald, P. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00605 · Cited by 69
Protein‐protein interactions as antibiotic targets: A medicinal chemistry perspective
Cossar, P. J., Lewis, P. J., & McCluskey, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21519 · Cited by 55
CBFβ is critical for AML1-ETO and TEL-AML1 activity
Roudaia, L., Cheney, M. D., Manuylova, E., Chen, W., Morrow, M., Park, S., Lee, C.-T., Kaur, P., Williams, O., Bushweller, J. H., et al. (2009) · Blood · doi:10.1182/blood-2008-03-147207 · Cited by 59
Identification of small-molecule inhibitors of the JIP–JNK interaction
Chen, T., Kablaoui, N., Little, J., Timofeevski, S., Tschantz, W. R., Chen, P., Feng, J., Charlton, M., Stanton, R., & Bauer, P. (2009) · Biochemical Journal · doi:10.1042/bj20081899 · Cited by 55
Rational design of protein–protein interaction inhibitors
Rognan, D. (2015) · MedChemComm · doi:10.1039/c4md00328d · Cited by 61
Conformational ensembles, signal transduction and residue hot spots: application to drug discovery.
Acuner, S. E., Gürsoy, A., Keskin, Ö., & Nussinov, R. (2010) · PubMed · Cited by 65
Goshisht, M. K., Moudgil, L., Rani, M., Khullar, P., Singh, G., Kumar, H., Singh, N., Kaur, G., & Bakshi, M. S. (2014) · The Journal of Physical Chemistry C · doi:10.1021/jp5078054 · Cited by 55
Clackson, T. (2005) · Nature Chemical Biology · doi:10.1038/nchembio0106-14 · Cited by 55
Chemical approaches to transcriptional regulation
Majmudar, C. Y., & Mapp, A. K. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.08.012 · Cited by 66
miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3
Zhou, Y., Dang, J., Chang, K.-Y., Yau, E., Aza-Blanc, P., Moscat, J., & Rana, T. M. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2936 · Cited by 54
“Because of the absence of well-defined binding pockets at key active sites (3), efforts to inhibit KRAS activity with small molecules have been largely fruitless (4–6).”
BackgroundBiomolecular condensates: hubs of Hippo-YAP/TAZ signaling in cancer
Kiang, K. M. Y., Ahad, L., Zhong, X., & Lu, Q. R. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.04.009 · Cited by 62
Structure-Based Design of Small-Molecule Protein–Protein Interaction Modulators: The Story so Far
Falchi, F., Caporuscio, F., & Recanatini, M. (2014) · Future Medicinal Chemistry · doi:10.4155/fmc.13.204 · Cited by 53
Isoquinolin‐1‐one Inhibitors of the MDM2–p53 Interaction
Rothweiler, U., Czarna, A., Krajewski, M., Ciombor, J., Kalinski, C., Khazak, V., Roß, G., Skobeleva, N., Weber, L., & Holak, T. A. (2008) · ChemMedChem · doi:10.1002/cmdc.200800025 · Cited by 64
Takahashi, H., Takahashi, C., Moreland, N. J., Chang, Y., Sawasaki, T., Ryo, A., Vasudevan, S. G., Suzuki, Y., & Yamamoto, N. (2012) · Antiviral Research · doi:10.1016/j.antiviral.2012.09.023 · Cited by 54
“Hence, it is becoming evident that the hot-spots of protein–protein interfaces are suitable targets for novel therapeutic drugs (Arkin and Wells, 2004; Buchwald, 2010; Pagliaro et al., 2004; Ryan and Matthews, 2005) Although the X-ray structure of NS3 complexed with NS5 is not available, previous studies with truncate…”
BackgroundCierpicki, T., & Grembecka, J. (2015) · Immunological Reviews · doi:10.1111/imr.12244 · Cited by 53
“It was believed that targeting PPI interfaces is too difficult due to: (i) unfavorable topology of PPI interfaces, (ii) lack of natural small molecules that bind to PPI interfaces, (iii) lack of appropriate screening libraries (23, 187, 188).”
BackgroundBarlow, Ν., Chalmers, D. K., Williams‐Noonan, B. J., Thompson, P. E., & Norton, R. S. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00218 · Cited by 56
Rakers, C., Bermudez, M., Keller, B. G., Mortier, J., & Wolber, G. (2015) · WIREs Computational Molecular Science · doi:10.1002/wcms.1222 · Cited by 55
“11 These protein domains with key interacting residues are termed hot spots, 12 and hot spot detection is an efficient strategy to identify potential druggable areas of PPIs.”
BackgroundBoström, J., Grant, J., Fjellström, O., Thelin, A., & Gustafsson, D. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm301818g · Cited by 53
Iegre, J., Gaynord, J. S., Robertson, N., Sore, H. F., Hyvönen, M., & Spring, D. R. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800052 · Cited by 55
Building Signaling Complexes at the Membrane
Cho, W. (2006) · Science s STKE · doi:10.1126/stke.3212006pe7 · Cited by 59
“high affinity, as seen in antibody-antigen recognition (17).”
BackgroundWang, H., Duennwald, M. L., Roberts, B. E., Rozeboom, L. M., Zhang, Y. L., Steele, A. D., Krishnan, R., Su, L. J., Griffin, D., Mukhopadhyay, S., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801934105 · Cited by 53
“Dogma holds that it is inherently difficult for small molecules of limited steric bulk to disrupt protein–protein interfaces because of their large, flat surface area (750–1,500 Å2), which seems to offer limited opportunities for small-molecule insertion (4).”
BackgroundInfluentialProtein interaction affinity determination by quantitative FRET technology
Song, Y., Rodgers, V. G. J., Schultz, J. S., & Liao, J. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24564 · Cited by 53
“After the genomic era, large-scale and genome-wide mapping protein–protein interactions can provide comprehensive understanding of protein interaction networks in cells and potential new drug targets (Arkin and Wells, 2004; Berg, 2008; Yin and Hamilton, 2005).”
BackgroundTreatment of Rare Inflammatory Kidney Diseases: Drugs Targeting the Terminal Complement Pathway
Anliker‐Ort, M., Dingemanse, J., van den Anker, J., & Kaufmann, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.599417 · Cited by 57
Emamjomeh, A., Goliaei, B., Zahiri, J., & Ebrahimpour, R. (2014) · Molecular BioSystems · doi:10.1039/c4mb00410h · Cited by 54
Simões, I. C. M., Costa, I. P. D., Coimbra, J. T. S., Ramos, M. J., & Fernandes, P. A. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00378 · Cited by 53
Perricone, U., Gulotta, M. R., Lombino, J., Parrino, B., Cascioferro, S., Diana, P., Cirrincione, G., & Padova, A. (2018) · MedChemComm · doi:10.1039/c8md00166a · Cited by 57
Advanced Methods for Accessing Protein Shape-Shifting Present New Therapeutic Opportunities
Knoverek, C. R., Amarasinghe, G. K., & Bowman, G. R. (2019) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.11.007 · Cited by 55
“For example, protein-protein interactions are notoriously difficult to target because the relevant binding sites are often too flat for a small molecule to bind tightly [39].”
BackgroundAlday, P. H., & Correia, J. J. (2009) · Biochemistry · doi:10.1021/bi900776u · Cited by 52
Tang, J. Y., Park, J. G., Millard, C. B., Schmidt, J. J., & Pang, Y. (2007) · PLoS ONE · doi:10.1371/journal.pone.0000761 · Cited by 52
Design of Cyclic Peptides Targeting Protein–Protein Interactions Using AlphaFold
(2023) · doi:10.3390/ijms241713257 · Cited by 51
A cryptic pocket in Ebola VP35 allosterically controls RNA binding
Cruz, M. A., Frederick, T. E., Mallimadugula, U. L., Singh, S., Vithani, N., Zimmerman, M. I., Porter, J. R., Moeder, K. E., Amarasinghe, G. K., & Bowman, G. R. (2022) · Nature Communications · doi:10.1016/j.bpj.2021.11.2561 · Cited by 54
Zhang, X., Jiang, L., Weng, G., Shen, C., Zhang, O., Liu, M., Zhang, C., Gu, S., Wang, J., Wang, X., et al. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf379 · Cited by 54
“Elucidating the 3D structures of protein complexes is crucial for deciphering biological pathways and gaining insights into the molecular mechanisms of PPIs [ 2–5 ].”
Using Peptides to Study Protein–Protein Interactions
Benyamini, H., & Friedler, A. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.196 · Cited by 53
Liang, W., Wang, S., Festa, F., Wiktor, P. J., Wang, W., Magee, M., LaBaer, J., & Tao, N. J. (2014) · Analytical Chemistry · doi:10.1021/ac5024556 · Cited by 52
Mcl-1 inhibitors: a patent review
Chen, L., & Fletcher, S. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1249848 · Cited by 54
Rapid Assembly of Matrix Metalloprotease Inhibitors Using Click Chemistry
Wang, J., Uttamchandani, M., Li, J., Hu, M., & Yao, S. Q. (2006) · Organic Letters · doi:10.1021/ol061431a · Cited by 58
Zhou, H., Wang, D.-A., Baldini, L., Ennis, E., Jain, R. K., Carie, A., Sebti, S. M., & Hamilton, A. D. (2006) · Organic & Biomolecular Chemistry · doi:10.1039/b515483a · Cited by 52
The structural biology of voltage-gated calcium channel function and regulation
Petegem, F. V., & Minor, D. L. (2006) · Biochemical Society Transactions · doi:10.1042/bst0340887 · Cited by 69
PCSK9: an emerging target for treatment of hypercholesterolemia
Duff, C. J., & Hooper, N. M. (2011) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2011.547480 · Cited by 49
“Unfortunately, it is often difficult to disrupt protein--protein interactions using such agents [73].”
BackgroundKonstantinidou, M., Visser, E. J., Vandenboorn, E., Chen, S., Jaishankar, P., Overmans, M., Dutta, S., Neitz, R. J., Renslo, A. R., Ottmann, C., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c05161 · Cited by 51
Self-citationProteomic Approaches and Identification of Novel Therapeutic Targets for Alcoholism
Gorini, G., Harris, R. A., & Mayfield, R. D. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.182 · Cited by 52
“This strategy has emerged as an important subfield in medication development (Arkin and Wells, 2004; Dev, 2004; Reilly et al, 2009), although PPIs do not always have detectable effects.”
BackgroundEngineering Peptide Inhibitors To Overcome PDZ Binding Promiscuity
Vouillème, L., Cushing, P. R., Volkmer, R., Madden, D. R., & Boisguérin, P. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.201005575 · Cited by 51
Minor, D. L. (2007) · Neuron · doi:10.1016/j.neuron.2007.04.026 · Cited by 57
“Why is this a useful thing to know? Such clarification is essential for designing ways to disrupt the interaction, whether that is to maximize the impact of mutagenesis in a functional study or to achieve the ultimate design of small molecules that can be used as research tools or even drugs (Arkin and Wells, 2004).”
BackgroundStroik, D. R., Yuen, S. L., Janicek, K. A., Schaaf, T. M., Li, J., Ceholski, D. K., Hajjar, R. J., Cornea, R. L., & Thomas, D. D. (2018) · Scientific Reports · doi:10.1038/s41598-018-29685-z · Cited by 54
Triazol: A Privileged Scaffold for Proteolysis Targeting Chimeras
Xia, L., Ba, M.-Y., Liu, W., Cheng, W., Hu, C.-P., Zhao, Q., Yao, Y., Sun, M., & Duan, Y. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0159 · Cited by 52
Pharmacological Rationale for Targeting IL-17 in Asthma
Rahmawati, S. F., Velde, M. T., Kerstjens, H. A. M., Dömling, A. S. S., Groves, M. R., & Gosens, R. (2021) · Frontiers in Allergy · doi:10.3389/falgy.2021.694514 · Cited by 54
Carvalho, G., Fabre, C., Braun, T., Grosjean, J., Adès, L., Agou, F., Tasdemir, E., Boehrer, S., Israël, A., Véron, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1210043 · Cited by 50
“However, recent developments suggest that such interaction domains may constitute a prospective target for small molecule inhibitors (”
BackgroundAye, Y., Brignole, E. J., Long, M. J. C., Chittuluru, J. R., Drennan, C. L., Asturias, F. J., & Stubbe, J. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.05.015 · Cited by 54
“Alterations of quaternary states of a protein can change its function dramatically (Nooren and Thornton, 2003; Arkin and Wells, 2004; Peihler, 2005).”
BackgroundScreening of Protein–Protein Interaction Modulators via Sulfo-Click Kinetic Target-Guided Synthesis
Kulkarni, S. S., Hu, X., Doi, K., Wang, H., & Manetsch, R. (2011) · ACS Chemical Biology · doi:10.1021/cb200085q · Cited by 53
Heeres, J. T., & Hergenrother, P. J. (2011) · Chem. Soc. Rev. · doi:10.1039/b923660k · Cited by 49
Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein
Hayouka, Z., Hurevich, M., Levin, A., Benyamini, H., Iosub‐Amir, A., Maes, M., Shalev, D. E., Loyter, A., Gilon, C., & Friedler, A. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.09.046 · Cited by 53
Protein interaction networks as starting points to identify novel antimicrobial drug targets
Zoraghi, R., & Reiner, N. E. (2013) · Current Opinion in Microbiology · doi:10.1016/j.mib.2013.07.010 · Cited by 55
“Antibacterial PIN-based drug discovery would be crucially augmented by the availability of orthogonal methods of characterization including computational screening, fragment-based discovery, mutagenesis, epitope mapping and structural biology [23,78–80,81 ].”
MethodDiscovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent
Lü, X., Liu, Y., Orvig, C., Liang, H., & Chen, Z. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b02047 · Cited by 52
Kinetic Microscale Thermophoresis for Simultaneous Measurement of Binding Affinity and Kinetics
Stein, J., Ianeselli, A., & Braun, D. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202101261 · Cited by 49
LG186: An Inhibitor of GBF1 Function that Causes Golgi Disassembly in Human and Canine Cells
Boal, F., Guetzoyan, L. J., Sessions, R. B., Zeghouf, M., Spooner, R. A., Lord, J. M., Cherfils, J., Clarkson, G. J., Roberts, L. M., & Stephens, D. J. (2010) · Traffic · doi:10.1111/j.1600-0854.2010.01122.x · Cited by 56
Fuwa, H., Kawakami, M., Noto, K., Muto, T., Suga, Y., Konoki, K., Yotsu‐Yamashita, M., & Sasaki, M. (2013) · Chemistry - A European Journal · doi:10.1002/chem.201300664 · Cited by 48
Histone Variant H2A.Z Can Serve as a New Target for Breast Cancer Therapy
Rangasamy, D. (2010) · Current Medicinal Chemistry · doi:10.2174/092986710792231941 · Cited by 51
Kelleher, M., Fruhwirth, G. O., Patel, G. S., Ofo, E., Festy, F., Barber, P. R., Ameer‐Beg, S., Vojnovic, B., Gillett, C., Coolen, A. C. C., et al. (2009) · Targeted Oncology · doi:10.1007/s11523-009-0116-y · Cited by 53
“Following successes in cancer therapy derived from targeting the MDM2-p53 interaction [12–14], the importance of protein-protein interactions is increasingly recognized, both for understanding cell physiology and for developing novel treatments [ 15 ].”
BackgroundBotulinum Neurotoxin A Protease: Discovery of Natural Product Exosite Inhibitors
Šilhár, P., Čapková, K., Salzameda, N. T., Barbieri, J. T., Hixon, M. S., & Janda, K. D. (2010) · Journal of the American Chemical Society · doi:10.1021/ja910761y · Cited by 48
Trabocchi, A., Menchi, G., Cini, N., Bianchini, F., Raspanti, S., Bottoncetti, A., Pupi, A., Calorini, L., & Guarna, A. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100754z · Cited by 54
Lee, D., Lee, S., Choi, J., Song, Y.-K., Kim, M. J., Shin, D., Bae, M. A., Kim, Y., Park, C., Lee, K., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00211 · Cited by 50
G Protein β γ Subunits as Targets for Small Molecule Therapeutic Development
Smrcka, A., Lehmann, D. M., & Dessal, A. L. (2008) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620708784534761 · Cited by 49
Cummings, M. D., Schubert, C., Parks, D. J., Calvo, R. R., LaFrance, L. V., Lattanze, J., Milkiewicz, K. L., & Lu, T. (2006) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2006.00365.x · Cited by 48
Segers, K., & Anné, J. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.04.007 · Cited by 53
Dimer-tetramer transition controls RUNX1/ETO leukemogenic activity
Wichmann, C. W., Becker, Y., Chen-Wichmann, L., Vogel, V., Vojtkova, A., Herglotz, J., Moore, S., Koch, J., Lausen, J., Mäntele, W., et al. (2010) · Blood · doi:10.1182/blood-2009-10-248047 · Cited by 55
“Also effective modulation of protein-protein interactions has been described for small-molecules binding to clefts or grooves at interface regions.(49,50) It appears promising”
BackgroundKinkade, R., Dasgupta, P., Carie, A., Pernazza, D., Carless, M. A., Pillai, S., Lawrence, N. J., Sebti, S. M., & Chellappan, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6672 · Cited by 48
“Whereas it has been difficult to generate small molecule inhibitors of protein-protein interactions that are clinically active ( 39 ), recent success in disrupting the hdm2-p53 (47) interaction shows that this is a viable strategy to develop novel anticancer drugs.”
BackgroundSaupe, J., Roske, Y., Schillinger, C., Kamdem, N., Radetzki, S., Diehl, A., Oschkinat, H., Krause, G., Heinemann, U., & Rademann, J. (2011) · ChemMedChem · doi:10.1002/cmdc.201100094 · Cited by 52
Quantification of HER family receptors in breast cancer
Nuciforo, P. G., Radosevic‐Robin, N., Ng, T., & Scaltriti, M. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0561-8 · Cited by 52
“Clinical application of protein-protein interactions has uncovered many potential targets for novel drug development or drug resistance mechanisms [45], with the MDM2-p53 interaction [46,47] and B-Raf inhibition being examples of recent successes [48].”
BackgroundPang, Y., Vummenthala, A., Mishra, R. K., Park, J. G., Wang, S., Davis, J., Millard, C. B., & Schmidt, J. J. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007730 · Cited by 46
“The latter has been a known challenge for decades [16].”
BackgroundForce spectroscopy studies on protein–ligand interactions: A single protein mechanics perspective
Hu, C., & Li, H. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.009 · Cited by 46
“Protein–ligand interactions, including protein–protein interactions, play essential biological roles in every aspect of living systems, and have found important applications in medicine and biotechnology [11].”
BackgroundTargeting protein-protein interaction interfaces in COVID-19 drug discovery
Chang, C., Lin, S., Satange, R., Lin, S., Sun, S.-C., Wu, H., Kehn‐Hall, K., & Hou, M. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.04.003 · Cited by 48
“Several excellent and detailed reviews have been written on the subject [55,56].”
Schön, A., Madani, N., Smith, A. B., LaLonde, J. M., & Freire, E. (2010) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2010.01075.x · Cited by 51
Wong, J. H., Alfatah, M., Sin, M. F., Sim, H. M., Verma, C. S., Lane, D. P., & Arumugam, P. (2017) · BMC Biology · doi:10.1186/s12915-017-0446-7 · Cited by 45
Druggable Orthosteric and Allosteric Hot Spots to Target Protein-protein Interactions
Ma, B., & Nussinov, R. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990073 · Cited by 45
Zhang, C., Tan, C. Y. J., Ge, J., Na, Z., Chen, G. Y. J., Uttamchandani, M., Sun, H., & Yao, S. Q. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201307803 · Cited by 46
The Overlap of Small Molecule and Protein Binding Sites within Families of Protein Structures
Davis, F. P., & Sali, A. (2010) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000668 · Cited by 45
“Although natural substrates often serve as guides for rational drug design, such information is rarely available for protein–protein interfaces [3].”
BackgroundNetwork-Based Strategies Can Help Mono- and Poly-pharmacology Drug Discovery: A Systems Biology View
Engin, H., Gürsoy, A., Nussinov, R., & Keskin, Ö. (2014) · Current Pharmaceutical Design · doi:10.2174/13816128113199990066 · Cited by 52
“There are a number of reviews [13, 15, 25, 31-35], which investigate PPI inhib-”
BackgroundBroad-Spectrum Proteome Editing with an Engineered Bacterial Ubiquitin Ligase Mimic
Ludwicki, M. B., Li, J., Stephens, E. A., Roberts, R. W., Koide, S., Hammond, P. T., & DeLisa, M. P. (2019) · ACS Central Science · doi:10.1021/acscentsci.9b00127 · Cited by 46
Siegel, M., Xia, J., & Khosla, C. (2007) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2007.06.020 · Cited by 46
Gunther, J. R., Moore, T. W., Collins, M. L., & Katzenellenbogen, J. A. (2008) · ACS Chemical Biology · doi:10.1021/cb800056r · Cited by 45
Metadata
- Authors
- Arkin, M. R., & Wells, J. A.
- Affiliations
- Sunesis (United States) (US)
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-04
- Volume
- 3
- Issue
- 4
- Pages
- 301-317
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2167398093
- Cited by
- 1,705
- References
- 178
- Citations by year
- 2026: 52 · 2025: 48 · 2024: 39 · 2023: 51 · 2022: 46 · 2021: 61 · 2020: 54 · 2019: 71 · 2018: 73 · 2017: 61 · 2016: 99 · 2015: 101 · 2014: 126 · 2013: 110 · 2012: 110
- FWCI
- 5.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- protein-protein interaction, small molecule inhibitors, drug discovery, binding pocket, therapeutic target, inhibitor characterization
- MeSH terms
- Animals, Binding Sites, Enzyme Inhibitors, Humans, Protein Binding, Proteins, Receptors, Cell Surface, Drug Design, Computational Biology
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.